Chemistry: molecular biology and microbiology – Spore forming or isolating process
Patent
1992-09-03
1996-01-23
Parr, Margaret
Chemistry: molecular biology and microbiology
Spore forming or isolating process
53038824, 5303881, 5303893, 5303891, 435 72, 435 793, C12N 512, C07K 1618, G01N 3353
Patent
active
054864720
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to an antibody which is novel and useful in that it has specific affinity for PACAP, and more particularly to an antibody useful for development of assays of PACAP on the basis of antigen-antibody reactions or for diagnosis and treatment of diseases related to PACAP.
Various hormones secreted by brain hypothalami and hypophyses have been known. Examples thereof include thyrotropin releasing hormone, luteinizing hormone releasing hormone, somatostatin, adrenocorticotropic hormone, growth hormone and prolactin. Action thereof has been studied in detail. Recently, a novel bioactive substance of hypothalamic origin other than these hormones was studied based upon adenylate cyclase activity, and consequently a peptide consisting of 38 amino acid residues which had not been reported till then was discovered from sheep hypothalami. This peptide was named "PACAP38NH.sub.2 " and has a structure represented by the following formula (SEQ ID NO:2): Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys Gln Arg Val Lys Asn Lys-NH.sub.2
It was disclosed in applications for patents (Japanese Patent Application Nos. 1-155791/1990 and 1-284771/1990) on cDNA of sheep PACAP38, and an application for a patent (Japanese Patent Application No. 1-259924/1990) on the partial structure of cDNA of human PACAP38 that the amino acid sequence of the mature portion of sheep PACAP38 was the same as that of human PACAP38, and that some amino acids of the precursors thereof were substituted. It is deduced from the position of continuous basic amino acids shown in the cDNA sequence of PACAP38NH.sub.2 that PACAP27NH.sub.2, in addition to PACAP38NH.sub.2, will exist as a peptide cut out of the precursor.
In fact, according to subsequent studies PACAP27NH.sub.2 was also isolated from sheep hypothalami, in addition to PACAP38NH.sub.2. The structure thereof is represented by the following formula (SEQ ID NO:2): Lys Lys Tyr Leu Ala Ala Val Leu-NH.sub.2
PACAP38NH.sub.2 and PACAP27NH.sub.2 are hereinafter represented by the general term of "PACAP". The 28 amino acid residues on the N-terminal side of PACAP38NH.sub.2 containing PACAP27NH.sub.2 show 68% homology with vasoactive intestinal polypeptide (VIP) well known as a brain-gut peptide. However, it has been reported that the adenylate cyclase activating activity of PACAP exceeds at least 1,000 times that of VIP.
Thus, the action of PACAP is anticipated to be different from that of VIP, and a deep interest is taken in the physiological role thereof and the relation thereof to the pathology.
Although the interest in PACAP is increased as described above, basic physiological information such as existing sites other than hypothalami of PACAP and a plasma level thereof is scarcely obtained, and the relation thereof to the pathology is also unknown. This is mainly caused by that any monoclonal antibodies specifically recognizing PACAP have hitherto not been prepared and that any immunoassays for assaying PACAP specifically and highly sensitively have not been developed. These immunological procedures are considered to be one of the most effective means to study PACAP, particularly the metabolic pathways thereof, the secretory mechanism thereof, the receptor system thereof, the relation thereof to the pathology and the like collectively. The establishment of these procedures has therefore been earnestly desired in various fields.
Previously, competitive radioimmunoassays (RIA) generally using one kind of antibody and enzyme immunoassays (EIA) have been developed and employed to assay low molecular weight peptides such as PACAP. On the other hand, sandwich immunoassays using two kinds of antibodies have the advantages of (1) improving the specificity of assay systems because of the use of two kinds of antibodies and (2) being little affected by nonspecific interfering factors because of the use of the antibodies in large excess to substances to be assayed. Until now, however, it has been unknown at all whether or not the low molecular weight peptid
REFERENCES:
Maurer, P. H. et al, Methods in Enzymology, 70:49-70, 1980.
Sevier, E. D., et al., Clin Chem., 27(11):1797-1806), 1981.
Dialog Information Service, File 154: Medline, accession No. 07391864.
Chemical Abstracts. vol. 99, 128, 11656lg, 1983.
Chemical Abstracts, vol. 86, 412, 187443, 1977.
Recueil, Journal of the Royal Netherlands Chemical Society, vol. 101, 393-396, 1982.
British Medical Bulletin, vol. 30, No. 1, 1974.
Elsevier Science Publishers B. V. 129-138, 1984.
Biochemical and Biophysical Research Communications vol. 164, No. 1, 567-574, 1989.
Biochemical and Biophysical Research Communications vol. 166, No. 1 81-89, 1990.
Kitada Chieko
Suzuki Nobuhiro
Tsuda Masao
Conlin David G.
Loring Susan A.
Parr Margaret
Resnick David S.
Takeda Chemical Industries Ltd.
LandOfFree
Monoclonal antibodies to PACAP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies to PACAP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies to PACAP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1504718